News

Citi Upgrades Cadence BanCorp Target Price Amid Growth Projections

Citi Upgrades Cadence BanCorp Target Price Amid Growth Projections

Citi Adjusts Cadence BanCorp Price Target

Citi has recently updated its outlook for Cadence BanCorp (NYSE: CADE), maintaining a Neutral rating while elevating the price target to $37 from $35. This revision comes as analysts foresee continued net interest margin (NIM) expansion paired with prudent cost management strategies that are expected to benefit the bank in the upcoming quarters.

Financial Health and Performance

The analysts provided insights into Cadence BanCorp's financial health, noting that even though growth rates are somewhat below expectations, the institution's fixed-asset repricing measures and sustained NIM growth are likely to enhance financial performance. Furthermore, the management's adept handling of core expenses has shown to effectively support core pre-provision net revenue (PPNR) trends.

Solid Credit Quality

The bank's credit quality remains robust, with prospects for an even stronger capital base. The current forecasts suggest that, despite a slowdown in loan growth, which was softer than earlier anticipated, this situation is expected to be temporary. The analyst indicated this softness is largely due to simultaneous payoffs affecting certain lending segments, rather than a decline in demand.

Future Growth Outlook

The new price target of $37 implies a $2 increment and reflects expectations that Cadence BanCorp will be able to mitigate deposit costs. Additionally, as the year concludes and paving the way towards the next year, the bank anticipates a gradual increase in its core loan growth, further influencing market perceptions positively.

Recent Q3 Results Highlight Strong Financial Position

In more recent developments, Cadence Bank showcased its strong Q3 2024 results, reporting a staggering GAAP net income of $134.1 million, equivalent to $0.72 per diluted share. This performance underscores the bank's resilient financial position.

Growing Customer Deposits

In the realm of customer engagement, Cadence Bank noted a significant quarter-over-quarter increase in adjusted net income from continuing operations, reaching $135.6 million, or $0.73 per share. Furthermore, the bank's core customer deposits indicated a year-over-year growth surge of over 11%, culminating in nearly $985 million, even as there has been a slight uptick in deposit costs.

Capital Strength and Share Repurchases

Emphasizing its strong capital standing, Cadence Bank reported a Common Equity Tier 1 (CET1) ratio of 12.3%. Additionally, the bank has undertaken the repurchase of more than 323,000 shares, showcasing confidence in its market position. Despite loan balances remaining stable due to notable payoffs, the institution is also pleased to observe robust new loan commitments and an enhanced net interest margin standing at 3.31%.

Strategic Insights and Future Plans

Cadence Bank's management has conveyed optimism regarding sustaining growth in loan originations while also looking forward to improving net interest margins. There are projections for revenue growth to potentially eclipse expense growth as the bank advances into 2025, with possible mergers and acquisitions also on the horizon as part of strategic expansion considerations.

Strong Stock Performance

Aligning with Citi's recent favorable outlook, Cadence BanCorp's stock performance has exhibited impressive upward momentum. Data indicates a total return of 68.93% over the past year, with the stock trading close to its 52-week maximum.

Frequently Asked Questions

What is the new price target for Cadence BanCorp set by Citi?

Citi has increased the price target for Cadence BanCorp to $37.

What factors are contributing to the positive outlook for Cadence Bank?

The outlook is supported by NIM expansion, effective cost management, and robust credit quality.

How did Cadence BanCorp perform in Q3 2024?

Cadence Bank reported a GAAP net income of $134.1 million and a strong growth in customer deposits.

What is Cadence Bank's current CET1 ratio?

The bank maintains a CET1 ratio of 12.3%, indicating strong capital strength.

What is the dividend yield for Cadence BanCorp?

Cadence BanCorp's dividend yield stands at 2.96%, with a growth rate of 6.38% over the past year.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

WIN Expands Global Family Support to 124 Countries

Updated Category News Views 55

WIN's Ambitious Global Expansion In the ever-twisting labyrinth of corporate benefits, WIN is stepping up its game. We're talking an expansion that balloons past traditional fertility offerings into a global medley of support services covering every conceivable family and health scenario. It ain’t just about making babies anymore. When you're dealing with 124 countries,...

Continue Reading
Protalix Unveils Promising Gout Therapy Data at ACR 2026

Updated Category News Views 31

A Glimmer of Hope for Gout Sufferers Uncontrolled gout patients may soon see a light at the end of the tunnel. Protalix BioTherapeutics (NYSE American: PLX) just rolled out data at the ACR Convergence 2026, underscoring the potential of their drug candidate, PRX-115. This revelation is a big deal for those grappling with gout that just won't quit, constantly pelted by...

Continue Reading
Xiaomi's Smart Auto Factory Draws Global Media Praise

Updated Category News Views 202

Xiaomi Impresses Global Media in Beijing Factory Tour In the ever-changing world of NEVs (New Energy Vehicles), a tour of Xiaomi's smart auto factory in Beijing has made waves among global media folks. These scribes got an up-close look at Xiaomi's magic mix of tech and style on November 6, part of a grand media gathering. What's Under the Hood? Marcos Costa de Oliveira,...

Continue Reading
EICMA 2026: Groundbreaking Moves in Two-Wheel World

Updated Category News Views 71

Revving Up in Milan: A Record-Breaking EICMA If you're into two-wheelers as much as stocks, EICMA 2026 is where all the action is happening. They opened the door with a bang at Fiera Milano Rho, pulling off their biggest showcase yet. Ten halls packed to the brim, up from nine the previous year, creating buzz across the globe. Showcasing 765 exhibitors and 2,142 brands...

Continue Reading
New Leadership at Reactive Tech: Claudio Facchin Steps In

Updated Category News Views 154

Facchin Joins Reactive Technologies: Power Play or Predictable Move? Let me tell you, the energy sector ain’t for the faint-hearted—especially when you’re talking grid stability. Reactive Technologies just tossed an ace on the table, appointing Claudio Facchin as the new Board Chairman. If you've been around the block, you might recognize Facchin's name from his...

Continue Reading
Leatt Gears Up for Q3 Results Conference Call

Updated Category News Views 106

A good heads-up, folks, isn't just about keeping helmets snug—it’s about knowing when to cash in, especially when Leatt Corporation's got their Q3 results ready to drop. November 12 is the big day, so circle that on your calendars. They're rolling out the numbers before the market even gets its coffee, possibly nudging the ticker, OTCQB:LEAT, in a ripple you’ll want...

Continue Reading
Target Hospitality's Growth and Earnings Analysis Q3 2026

Updated Category News Views 64

Strategic Transformation: A Mixed Bag of Results In the raucous world of high-stakes business, folks, Target Hospitality Corp. (NASDAQ: TH) is making quite the noise. For Q3 2026, they trumpeted a juicy $129.1 million in revenue, which is a solid notch up by 30% from a year before. Yet, like a seasoned trader facing a knife-edge call, they're handling a bittersweet...

Continue Reading
Energenesis Tackles Space Anemia with ATP Boost

Updated Category News Views 47

Gearing Up for Space Medicine: Enter Energenesis With the cosmic frontier drawing investor eyes and day-to-day operations inching skyward, here comes Energenesis Biomedical (TWSE: 6657), poking its head into space medicine. This isn’t just another biotech firm looking to throw drugs at terrestrial problems. No, Energenesis shot its shot at TASTI 2026 with its...

Continue Reading
Veterinary Stories Transform Pet Care in New Docuseries

Updated Category News Views 132

Peeling Back the Scrubs: Hidden Heroes in Vet Medicine Everyone's all-hands-on-deck when it's your furball on the line, but how much do you really know about what happens in those vet offices? Finally, National Veterinary Associates (NVA) is unzipping that mystery with a no-bones-about-it docuseries, Advancing Veterinary Medicine: Our Stories, right out of Austin, Texas....

Continue Reading
Zabalafin Hydrogel: Promise in Treating Atopic Dermatitis

Updated Category News Views 55

Pioneering a New Path in Dermatology Treatment In the world of dermatology, finding a topical solution that tackles the full spectrum of atopic dermatitis (AD) is as rare as hens' teeth. But here's a twist—in a recent research paper gracing the Journal of Drugs in Dermatology, Alphyn Biologics sheds light on their unique contender, Zabalafin Hydrogel. This ain't your...

Continue Reading

Top 5 Most Recently Viewed Articles

Qatar Airways Reveals New Lounge and Terminal at JFK Airport

Updated Category News Views 254

Qatar Airways Expands Presence at JFK Airport Qatar Airways is set to enhance its operations at John F. Kennedy International Airport by moving to the New Terminal One, which promises a first-of-its-kind experience for travelers in the United States. This airline, renowned for its exceptional service, is preparing to introduce a dedicated lounge in 2026, significantly...

Continue Reading
Venture Global Faces Class Action Amid Legal Challenges

Updated Category News Views 227

Venture Global Faces Legal Action Venture Global, Inc. has recently been embroiled in a securities class action lawsuit filed in the Southern District of New York. The lawsuit pertains to all individuals or entities who acquired Venture's securities during its initial public offering around January 2025, seeking to recover damages under federal securities laws. Claims of...

Continue Reading
Join Aclaris Therapeutics' R&D Day on Immuno-Inflammatory Gaps

Updated Category News Views 151

Aclaris Therapeutics R&D Day Focused on Patient Needs Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a biopharmaceutical organization based in Pennsylvania, is set to host its highly anticipated R&D Day. This event is dedicated to exploring the evolving landscape of immuno-inflammatory diseases and the innovative solutions that the company is developing. The R&D Day will take...

Continue Reading
Cloudelligent Achieves Sixth Ranking in Global MSP List

Updated Category News Views 137

Cloudelligent Celebrates Top Ranking in MSP 501 Cloudelligent, a prominent Managed Cloud Services provider, has reached an impressive milestone by being recognized as the sixth-ranked company on Channel Futures' prestigious MSP 501 list for the year. This distinction is not merely a testament to their robust performance; it underscores their relentless commitment to...

Continue Reading
Lithia Motors Sees Earnings Growth, Yet Shares Decline

Updated Category News Views 116

Lithia Motors Reports Strong Financial Performance Why are Lithia Motors, Inc.‘s shares slipping despite a substantial earnings beat and impressive profitability growth? As investors grapple with mixed signals from the company’s latest financial performance, the story behind the numbers holds the key to understanding market reactions. Lithia Motors shares are trading...

Continue Reading